Acorda CTO Batycky is jumping ship to run a biotech; Motif gets a PDUFA date

→ We have one more news item about a biotech exec on the move. Acorda‘s $ACOR chief technology officer Rick Batycky is leaving the company to take the CEO job at an undisclosed private biotech. David Lawrence, Acorda’s chief of business operations, is being charged with the company’s Chelsea, MA manufacturing facility, which produces Inbrija, now under regulatory review as Acorda braces for generic competition to Ampyra.

Motif Bio says the FDA has accepted its NDA for iclaprim, an antibiotic for acute bacterial skin and skin structure infections. Motif is facing a PDUFA date of February 13, 2019.

→ Boston-based Stealth BioTherapeutics says it is advancing a new drug candidate to IND stage with the help of its partners at Evotec. The biotech is working on a pipeline of drugs related to mitochondrial dysfunction.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->